GGrantIndex
← Leaderboards

Geoffrey L Chupp

University Of California, San Diego

$12,482,471
Attributed
$21,158,569
Total exposure
6
Grants
4
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $2.5M · FY200825
$5M$3.8M$2.5M$1.3M$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$21,158,569 · 6

By mechanism

R01$12,813,185 · 3
UH3$4,532,610 · 1
UH2$3,286,814 · 1
K08$525,960 · 1

Top collaborators

Most similar at University Of California, San Diego

Same institution · by research overlap

Others in their field

Top investigators on “Sputum

Research focus

SputumBloodAsthmaCellsPathway InteractionsGenesLungRespiratory PhysiologyChitinaseBlood CirculationProteinsChronicPathogenesisSubgroupInterleukin-13SymptomsTranscriptomicsCohortResponseGenomicsPhenotypeInflammatorySeveritiesBase

Grant awards (21)

Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping$2,137,425
R01 · FY2025 · HL
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping$2,102,471
R01 · FY2024 · HL
Leveraging Pharmacogenomics in Asthma for Predication, Mechanism and Endotyping$2,115,286
R01 · FY2022 · HL
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,628,646
UH3 · FY2018 · HL · contact PI
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,645,902
UH3 · FY2017 · HL · contact PI
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,258,062
UH3 · FY2016 · HL · contact PI
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma$769,035
R01 · FY2016 · HL · contact PI
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,623,663
UH2 · FY2015 · HL · contact PI
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma$840,882
R01 · FY2015 · HL · contact PI
Pre-Clinical Development of a Novel Anti-YKL-40 Biologic to Treat Severe Asthma$1,663,151
UH2 · FY2014 · HL · contact PI
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma$794,768
R01 · FY2014 · HL · contact PI
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma$63,294
R01 · FY2014 · HL · contact PI
Longitudinal Analysis of Transcriptomic Endophenotypes in Asthma$790,368
R01 · FY2013 · HL · contact PI
Gene Expression Profiling in Asthma Severity: CHI3L1 Genotypes and Serum YKL-40$765,917
R01 · FY2011 · HL · contact PI
Gene Expression Profiling in Asthma Severity: CHI3L1 Genotypes and Serum YKL-40$793,521
R01 · FY2010 · HL · contact PI
Gene Expression Profiling in Asthma Severity: CHI3L1 Genotypes and Serum YKL-40$820,377
R01 · FY2009 · HL · contact PI
Gene Expression Profiling in Asthma Severity: CHI3L1 Genotypes and Serum YKL-40$819,841
R01 · FY2008 · HL · contact PI
BIOLOGY OF IL-16 IN IL-1680 AND IL-1614 TRANSGENIC MICE$131,490
K08 · FY2003 · HL
BIOLOGY OF IL-16 IN IL-1680 AND IL-1614 TRANSGENIC MICE$131,490
K08 · FY2002 · HL
BIOLOGY OF IL-16 IN IL-1680 AND IL-1614 TRANSGENIC MICE$131,490
K08 · FY2001 · HL
BIOLOGY OF IL-16 IN IL-1680 AND IL-1614 TRANSGENIC MICE$131,490
K08 · FY2000 · HL